Literature DB >> 25934841

Gleaning relapse risk from B cell phenotype: decreased CD5+ B cells portend a shorter time to relapse after B cell depletion in patients with ANCA-associated vasculitis.

Donna O Bunch1, Carmen E Mendoza1, Lydia T Aybar1, Elizabeth S Kotzen1, Kerry R Colby1, Yichun Hu1, Susan L Hogan1, Caroline J Poulton1, John L Schmitz2, Ronald J Falk1, Patrick H Nachman1, William F Pendergraft1, JulieAnne G McGregor1.   

Abstract

Entities:  

Keywords:  Autoimmune Diseases; B cells; Disease Activity; Granulomatosis with polyangiitis; Systemic vasculitis

Mesh：

Substances：

Year:  2015        PMID： 25934841      PMCID： PMC4534316          DOI： 10.1136/annrheumdis-2014-206756

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  10 in total

1.  Use of CD45 gating in three and four-color flow cytometric immunophenotyping: guideline from the National Institute of Allergy and Infectious Diseases, Division of AIDS.

Authors:  Carol T Schnizlein-Bick; Francis F Mandy; Maurice R G O'Gorman; Helene Paxton; Janet K A Nicholson; Lance E Hultin; Rebecca S Gelman; Cynthia L Wilkening; Daniella Livnat
Journal:  Cytometry       Date:  2002-04-15

2.  Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

Authors:  John H Stone; Peter A Merkel; Robert Spiera; Philip Seo; Carol A Langford; Gary S Hoffman; Cees G M Kallenberg; E William St Clair; Anthony Turkiewicz; Nadia K Tchao; Lisa Webber; Linna Ding; Lourdes P Sejismundo; Kathleen Mieras; David Weitzenkamp; David Ikle; Vicki Seyfert-Margolis; Mark Mueller; Paul Brunetta; Nancy B Allen; Fernando C Fervenza; Duvuru Geetha; Karina A Keogh; Eugene Y Kissin; Paul A Monach; Tobias Peikert; Coen Stegeman; Steven R Ytterberg; Ulrich Specks
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

3.  Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

Authors:  Rachel B Jones; Jan Willem Cohen Tervaert; Thomas Hauser; Raashid Luqmani; Matthew D Morgan; Chen Au Peh; Caroline O Savage; Mårten Segelmark; Vladimir Tesar; Pieter van Paassen; Dorothy Walsh; Michael Walsh; Kerstin Westman; David R W Jayne
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

4.  Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  E M Miloslavsky; U Specks; P A Merkel; P Seo; R Spiera; C A Langford; G S Hoffman; C G M Kallenberg; E W St Clair; N K Tchao; L Viviano; L Ding; D Iklé; M Villarreal; B Jepson; P Brunetta; N B Allen; F C Fervenza; D Geetha; K Keogh; E Y Kissin; P A Monach; T Peikert; C Stegeman; S R Ytterberg; J H Stone
Journal:  Arthritis Rheumatol       Date:  2014-11       Impact factor: 10.995

5.  Decreased CD5⁺ B cells in active ANCA vasculitis and relapse after rituximab.

Authors:  Donna O'Dell Bunch; JulieAnne G McGregor; Nirmal B Khandoobhai; Lydia T Aybar; Madelyn E Burkart; Yichun Hu; Susan L Hogan; Caroline J Poulton; Elisabeth A Berg; Ronald J Falk; Patrick H Nachman
Journal:  Clin J Am Soc Nephrol       Date:  2013-01-04       Impact factor: 8.237

6.  Efficacy of remission-induction regimens for ANCA-associated vasculitis.

Authors:  Ulrich Specks; Peter A Merkel; Philip Seo; Robert Spiera; Carol A Langford; Gary S Hoffman; Cees G M Kallenberg; E William St Clair; Barri J Fessler; Linna Ding; Lisa Viviano; Nadia K Tchao; Deborah J Phippard; Adam L Asare; Noha Lim; David Ikle; Brett Jepson; Paul Brunetta; Nancy B Allen; Fernando C Fervenza; Duvuru Geetha; Karina Keogh; Eugene Y Kissin; Paul A Monach; Tobias Peikert; Coen Stegeman; Steven R Ytterberg; Mark Mueller; Lourdes P Sejismundo; Kathleen Mieras; John H Stone
Journal:  N Engl J Med       Date:  2013-08-01       Impact factor: 91.245

7.  Reduced CD5(+) CD24(hi) CD38(hi) and interleukin-10(+) regulatory B cells in active anti-neutrophil cytoplasmic autoantibody-associated vasculitis permit increased circulating autoantibodies.

Authors:  L T Aybar; J G McGregor; S L Hogan; Y Hu; C E Mendoza; E J Brant; C J Poulton; C D Henderson; R J Falk; D O Bunch
Journal:  Clin Exp Immunol       Date:  2015-05       Impact factor: 4.330

8.  Human CD5 promotes B-cell survival through stimulation of autocrine IL-10 production.

Authors:  Hélène Gary-Gouy; Julie Harriague; Georges Bismuth; Cornelia Platzer; Christian Schmitt; Ali H Dalloul
Journal:  Blood       Date:  2002-08-08       Impact factor: 22.113

9.  Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis.

Authors:  William F Pendergraft; Frank B Cortazar; Julia Wenger; Andrew P Murphy; Eugene P Rhee; Karen A Laliberte; John L Niles
Journal:  Clin J Am Soc Nephrol       Date:  2014-03-13       Impact factor: 8.237

10.  Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener's). Results of a single-center cohort study on 66 patients.

Authors:  Ana Luisa Calich; Xavier Puéchal; Grégory Pugnet; Jonathan London; Benjamin Terrier; Pierre Charles; Luc Mouthon; Loïc Guillevin
Journal:  J Autoimmun       Date:  2014-04-02       Impact factor: 7.094
  10 in total
  8 in total

Review 1.  Could Lymphocyte Profiling be Useful to Diagnose Systemic Autoimmune Diseases?

Authors:  Guillermo Carvajal Alegria; Pierre Gazeau; Sophie Hillion; Claire I Daïen; Divi Y K Cornec
Journal:  Clin Rev Allergy Immunol       Date:  2017-10       Impact factor: 8.667

Review 2.  Update on ANCA-associated vasculitis: from biomarkers to therapy.

Authors:  Martina Tedesco; Maurizio Gallieni; Francesca Pellegata; Mario Cozzolino; Federico Alberici
Journal:  J Nephrol       Date:  2019-07-12       Impact factor: 3.902

Review 3.  The Role of Regulatory B cells in Kidney Diseases.

Authors:  Wang Long; Hedong Zhang; Wenjia Yuan; Gongbin Lan; Zhi Lin; Longkai Peng; Helong Dai
Journal:  Front Immunol       Date:  2021-05-24       Impact factor: 7.561

4.  Highly Sensitive Flow Cytometric Detection of Residual B-Cells After Rituximab in Anti-Neutrophil Cytoplasmic Antibodies-Associated Vasculitis Patients.

Authors:  Laura S van Dam; Jelle M Oskam; Sylvia W A Kamerling; Eline J Arends; O W Bredewold; Magdalena A Berkowska; Jacques J M van Dongen; Ton J Rabelink; Cees van Kooten; Y K Onno Teng
Journal:  Front Immunol       Date:  2020-12-15       Impact factor: 7.561

Review 5.  Effector and regulatory B cells in immune-mediated kidney disease.

Authors:  Claudia Mauri; Alan D Salama; Kristine Oleinika
Journal:  Nat Rev Nephrol       Date:  2019-01       Impact factor: 28.314

Review 6.  B Cell Therapies, Approved and Emerging: a Review of Infectious Risk and Prevention During Use.

Authors:  Md Yuzaiful Md Yusof; Edward M Vital; Maya H Buch
Journal:  Curr Rheumatol Rep       Date:  2015-10       Impact factor: 4.592

Review 7.  Recent advances in understanding of the pathogenesis of ANCA-associated vasculitis.

Authors:  Maria Prendecki; Charles D Pusey
Journal:  F1000Res       Date:  2018-07-19

8.  Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation.

Authors:  Yusuke Miyazaki; Shingo Nakayamada; Satoshi Kubo; Yuichi Ishikawa; Maiko Yoshikawa; Kei Sakata; Shigeru Iwata; Ippei Miyagawa; Kazuhisa Nakano; Yoshiya Tanaka
Journal:  Arthritis Res Ther       Date:  2020-06-15       Impact factor: 5.156
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.